Steven L. Hoerter

Steven L. Hoerter (chief executive) discloses dealings in 3 companies, chiefly Deciphera Pharmaceuticals, Inc., Agios Pharmaceuticals, Inc. and MBX Biosciences, Inc. Over a trading history stretching from 23 January 2018 to 3 August 2026, the count stands at 52 filings.

Both buying and selling appear: 1 purchase worth €226k, against 14 sales worth €4.4M. Netting one side against the other leaves €4.1M of net selling. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 16 share grants and 19 option exercises.

Most recently, on 4 August 2026, the filings show a share grant in MBX Biosciences, Inc. The most recent open-market purchase was published on 20 October 2025, 369 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.